Consumption of oral anticoagulants in hospitals of the Russian Federation: analysis of the dynamics of procurement data

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Thromboembolic complications are the one the factors that plays a significant role in the increase in mortality and disability of the population. The main role in their treatment and prevention belongs to anticoagulants; incl. oral anticoagulants (OACs); which include rivaroxaban; apixaban and dabigatran. OACs have gained particular importance in the context of the novel coronavirus infection (COVID-19) pandemic.

Objective. Evaluation of the consumption of OACs in hospitals in the Russian Federation for the period from 2017 to 2022 and the characteristics of their consumption during the COVID-19 pandemic.

Methods. The database of OOO Cursor Marketing LLC was used as a data source. Data on contracts concluded between 01/01/2017 and 12/31/2022 were analyzed. Data published by WHO from March 1; 2020 to December 31; 2022 were used as a source of data on morbidity and mortality from COVID-19. Consumption was calculated based on DDD (Defined Daily Dose) data presented on the WHO Collaborating Center website.

Results. Total for the period 2017–2022. 57;866 records were entered into the Cursor databases; of which 47.38% of records contained an indication that the purchased drug was rivaroxaban; 26.51% – dabigatran and 26.11% – apixaban. There was a drop in the number of contracts in 2022; from 2017 to 2021; their number grew; with the increase being more pronounced for apixaban and the least significant for dabigatran. Similar dynamics were observed for the volume of contracts; expressed in the number of packages and DDD; 97% of all contracts were concluded for a period of one year. For all analyzed time series; the presence of seasonality was found. The number of packages purchased and the DDD of rivaroxaban (P<0.05) and apixaban (P<0.001) purchased were correlated with rates of new illness and death from COVID-19.

Conclusion. The problem of studying the dynamics of OAC consumption is of significant practical interest. The number of requests for the purchase of OACs in Russian hospitals is increasing; and the COVID-19 pandemic has had a significant impact on the procurement structure.

全文:

受限制的访问

作者简介

Aleksandr Matveev

Medical Academy of Continuous Professional Education

编辑信件的主要联系方式.
Email: matveevav@rmapo.ru
ORCID iD: 0000-0002-6636-3950
SPIN 代码: 8518-1320
Scopus 作者 ID: 37088844200
Researcher ID: 6168-2019

Cand. Sci. (Med.), Associate Professor at the Department of Clinical Pharmacology and Therapy n.a. acad. B.E. Votchaln

俄罗斯联邦, Moscow

S. Glagoleva

Medical Academy of Continuous Professional Education

Email: matveevav@rmapo.ru
Scopus 作者 ID: 57193931109

Department of Clinical Pharmacology and Therapy n.a. Acad. B.E. Votchaln

 

俄罗斯联邦, Moscow

D. Sychev

Medical Academy of Continuous Professional Education

Email: matveevav@rmapo.ru
ORCID iD: 0000-0002-4496-3680
SPIN 代码: 4525-7556
Scopus 作者 ID: 7801389135
Researcher ID: 6422-2018

Department of Clinical Pharmacology and Therapy n.a. Acad. B.E. Votchaln

俄罗斯联邦, Moscow

参考

  1. Strom B.L.; Kimmel S.E.; Hennessy S.; eds. Pharmacoepidemiology. Wiley; 2012. doi: 10.1002/9781119959946.
  2. WHO International Working Group for Drug Statistics Methodology; WHO Collaborating Centre for Drug Statistics Methodology; WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacology. Introduction to Drug Utilization Research. WHO; 2003. Accessed October 3; 2023. URL: https://www.who.int/publications/i/item/8280820396
  3. Чеберда А.Е. Исследования потребления лекарственных средств. Качественная клиническая практика. 2017;(1):42–5. [Cheberda A.E. Drug utilization studies. Quality Clin Pract. 2017;(1):42–5. (In Russ.)].
  4. Whitworth M.M.; Haase K.K.; Fike D.S.; et al. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gen Med. 2017;10:87. doi: 10.2147/IJGM.S129235.
  5. Dobesh P.P. Economic Burden of Venous Thromboembolism in Hospitalized Patients. Pharmacother. 2009;29(8):943–53. doi: 10.1592/phco.29.8.943.
  6. Lim G.B. Milestone 2: Warfarin: from rat poison to clinical use. Nature Publishing Group. Published on-line 2017. doi: 10.1038/nrcardio.2017.172.
  7. Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов; получающих оральные антикоагулянты. Терапия. 2021;10(51):23–41. [Expert consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Therapy. 2021;10(51):23–41. (In Russ.)].
  8. Временные методические рекомендации. Профилактика; диагностика и лечение новой коронавирусной инфекции (COVID-19). 8th ed. Министерство здравоохранения Российской Федерации; 2020. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf. [Temporary methodological recommendations. Prevention; Diagnosis and Treatment of Emerging Coronavirus Infection (COVID-19). 8th ed. Ministry of Health of the Russian Federation; 2020. (In Russ.)].URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf
  9. Клейменова Е.; Отделенов В.; Нигматкулова М. и др. Динамика применения антикоагулянтов в многопрофильном стационаре в 2008–2018 гг. Рациональная фармакотерапия в кардиологии. 2021;17(4):544–51. [Kleymenova E.; Otdelenov V.; Nigmatkulova M.; et al. Dynamics of anticoagulant use in a multidisciplinary hospital in 2008–2018. Rational Pharmacoth Cardiol. 2021;17(4):544–51. (In Russ.)]. doi: 10.20996/1819-6446-2021-08-10.
  10. Yan V.K.C.; Li H.L.; Wei L.; et al. Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019. Drugs. 2023;83(4):315–40. doi: 10.1007/s40265-023-01837-0.
  11. Navar M.; Kolkailah A.A.; Overton R.; et al. Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice; 2011 to 2020. J Am Heart Associat.: Cardiovasc. Cerebrovasc. Dis. 2022;11(22):26723. doi: 10.1161/JAHA.122.026723.
  12. Ho K.H.; van Hove M.; Leng G. Trends in anticoagulant prescribing: a review of local policies in English primary care. BMC. Health Serv Res. 2020;20(1):279. doi: 10.1186/s12913-020-5058-1.
  13. Alkhameys S.; Barrett R. Impact of the COVID-19 pandemic on England’s national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019–February 2021). Curr Med Res Opin. 2022;38(7):1081–92. doi: 10.1080/03007995.2022.2078100.
  14. Antonazzo I.C.; Fornari C.; Paoletti O.; et al. COVID-19 Outbreak Impact on Anticoagulants Utilization: An Interrupted Time-Series Analysis Using Health Care Administrative Databases. Thromb Haemost. 2021;121(08):1115–18. doi: 10.1055/a-1523-7658.
  15. Baybulatova E.A.; Chenkurov M.S.; Korovyako-va E.A.; et al. Direct Oral Anticoagulants Consumption and Expenditure in Covid-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use. Published online 2023. doi: 10.20944/preprints202311.0254.v1.
  16. DSM Group. Фармацевтический рынок России – 2022 г. 2023. Accessed November 15; 2023. URL: https://dsm.ru/docs/analytics/Annual_report_2023_rus.pdf. [DSM Group. Pharmaceutical Market in Russia – 2022. 2023. Accessed November 15; 2023. (In Russ.)].URL: https://dsm.ru/docs/analytics/Annual_report_2023_rus.pdf

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Number of annually announced contracts for the purchase of POAK for the period 2017-2022.

下载 (158KB)
索引源数据
3. Fig. 2. Number of announced contracts for the purchase of POAK per month for the period 2017-2022.

下载 (213KB)
索引源数据
4. Fig. 3. Delivery times under concluded contracts

下载 (86KB)
索引源数据
5. Fig. 4. The number of packages (A) and DDD of DOAC purchased annually by hospitals for the period 2017-2022.

下载 (228KB)
索引源数据
6. Fig. 5. Volumes of POAK deliveries per month, according to contracts concluded for the period 2017-2022, expressed in the number of packages (A) and DDD (B)

下载 (253KB)
索引源数据
7. Fig. 6. Number of new cases of COVID-19 and fatal cases in the Russian Federation for the period 2020-2022 (according to WHO data with changes)

下载 (184KB)
索引源数据

版权所有 © Bionika Media, 2023